Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19)

JAMA Netw Open. 2020 Aug 3;3(8):e2017539. doi: 10.1001/jamanetworkopen.2020.17539.

Authors

Morayma Reyes Gil¹, Mohammad Barouqa¹, James Szymanski¹, Jesus D Gonzalez-Lugo², Shafia Rahman², Henny H Billett^{2

3}

Affiliations

¹ Montefiore Medical Center, Department of Pathology, Albert Einstein College of Medicine, The Bronx, New York.
² Montefiore Medical Center, Division of Hematology, Department of Medical Oncology, Albert Einstein College of Medicine, The Bronx, New York.
³ Montefiore Medical Center, Department of Medicine, Albert Einstein College of Medicine, The Bronx, New York.

PMID: 32785632
DOI: 10.1001/jamanetworkopen.2020.17539

No abstract available

MeSH terms

Adult
Aged
Antiphospholipid Syndrome / complications
Betacoronavirus
C-Reactive Protein / metabolism
COVID-19
Coronavirus Infections / blood*
Coronavirus Infections / complications
Coronavirus Infections / virology
Female
Humans
Lupus Coagulation Inhibitor / blood*
Male
Middle Aged
Pandemics
Partial Thromboplastin Time
Pneumonia, Viral / blood*
Pneumonia, Viral / complications
Pneumonia, Viral / virology
SARS-CoV-2
Thrombosis / blood
Thrombosis / complications

Substances

Lupus Coagulation Inhibitor
C-Reactive Protein